Cancer Letters
Volume 208, Issue 1 , Pages 1-33 , 10 May 2004

Common gene polymorphisms, cancer progression and prognosis

Received 1 February 2004 ,Accepted 14 February 2004.

References 

  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  2. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al.  International SNP Map Working Group, A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928–933
  3. Subramanian G, Adams MD, Venter JC, Broder S. Implications of the human genome for understanding human biology and medicine. J. Am. Med. Assoc. 2001;286:2296–2307
  4. Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo. 1998;12:571–578
  5. In:  Vineis P,  Malats N,  Lang M,  d'Errico A,  Caporaso N,  Cuzick J,  Boffetta P editor. Metabolic Polymorphisms and Susceptibility to Cancer. Lyon: IARC Sci. Publ., 148, IARC; 1999;
  6. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. 2000;9:3–28
  7. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology. 2001;121:282–301
  8. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 2002;506-507:65–77
  9. Nebert DW, Roe AL, Vandale SE, Bingham,G E, Oakley G. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet. Med. 2002;4:62–70
  10. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002;17:463–469
  11. Ronen A, Glickman BW. Human DNA repair genes. Environ. Mol. Mutagen. 2001;37:241–283
  12. Wiencke JK. DNA adduct burden and tobacco carcinogenesis. Oncogene. 2002;21:7376–7391
  13. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677
  14. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348
  15. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103–112
  16. Simpson DJ, Fryer AA, Grossman AB, Wass JA, Pfeifer M, Kros JM, et al.  Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis. 2001;22:1801–1807
  17. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, et al.  Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257–264
  18. Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, et al.  Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int. J. Cancer. 2003;103:116–120
  19. Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J, et al.  Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 1998;4:2411–2418
  20. Dhar KK, Branigan K, Howells RE, Musgrove C, Jones PW, Strange RC, et al.  Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int. J. Gynecol. Cancer. 1999;9:342–347
  21. Zhang YJ, Chen SY, Chen CJ, Santella RM. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol. Carcinog. 2002;33:125–129
  22. McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J, et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int. J. Cancer. 2000;88:77–81
  23. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res. 2000;60:249–252
  24. Costea I, Moghrabi A, Krajinovic M. The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2003;13:577–580
  25. Holley SL, Parkes G, Matthias C, Bockmuhl U, Jahnke V, Leder K, et al.  Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am. J. Pathol. 2001;159:1917–1924
  26. Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, Hahka-Kemppinen M, et al.  Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer. 2000;28:404–414
  27. Sakano S, Berggren P, Kumar R, Steineck G, Adolfsson J, Onelov E, et al.  Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int. J. Cancer. 2003;104:98–103
  28. Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K, Wake N. WAF1 genotype and endometrial cancer susceptibility. Gynecol. Oncol. 1999;72:187–192
  29. Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis. 2002;23:311–315
  30. Zhang ZW, Newcomb P, Hollowood A, Feakins R, Moorghen M, Storey A, et al.  Age-associated increase of codon 72 arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin. Cancer Res. 2003;9:2151–2156
  31. Shih CM, Kuo YY, Wang YC, Jian SL, Hsu YT, Wu HY, et al. Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. Lung Cancer. 2002;36:125–132
  32. Dlugosz A, Adler G, Ciechanowicz A, Jaroszewicz-Heigelmann H, Starzynska T. EcoRI polymorphism of the L-myc gene in gastric cancer patients. Eur. J. Gastroenterol. Hepatol. 2002;14:1231–1235
  33. Shibuta K, Mori M, Haraguchi M, Yoshikawa K, Ueo H, Akiyoshi T. Association between restriction fragment length polymorphism of the L-myc gene and susceptibility to gastric cancer. Br. J. Surg. 1998;85:681–684
  34. Kondratieva TV, Imyanitov EN, Togo AV, Zaitseva OA, Yatsuk OS, Romanenko SM, et al.  L-MYC and GSTM1 polymorphisms are associated with unfavourable clinical parameters of gliomas. J. Exp. Clin. Cancer Res. 2000;19:197–200
  35. Ejarque MJ, Vicente M, Bernues M, Oliver A, Vicente J, Capella G, et al.  Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients. Br. J. Cancer. 1999;79:1855–1858
  36. Thunberg U, Tobin G, Johnson A, Soderberg O, Padyukov L, Hultdin M, et al.  Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet. 2002;360:1935–1939
  37. Toguchida J, McGee TL, Paterson JC, Eagle JR, Tucker S, Yandell DW, et al. Complete genomic sequence of the human retinoblastoma susceptibility gene. Genomics. 1993;17:535–543
  38. Rothberg PG, Ponnuru S, Baker D, Bradley JF, Freeman AI, Cibis GW, et al.  A deletion polymorphism due to Alu–Alu recombination in intron 2 of the retinoblastoma gene: association with human gliomas. Mol. Carcinog. 1997;19:69–73
  39. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, et al.  Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J. Biol. Chem. 2003;278:30339–30347
  40. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–1011
  41. Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, Macdonald F, et al.  Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene. 2002;21:1928–1933
  42. Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, et al. A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int. J. Cancer. 2001;95:388–393
  43. Bahl R, Arora S, Nath N, Mathur M, Shukla NK, Ralhan R. Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene. 2000;19:323–328
  44. Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V, Ohnishi T. Polymorphism of the WAF1 gene is related to susceptibility to cervical cancer in Japanese women. Int. J. Mol. Med. 2001;7:261–264
  45. Ralhan R, Agarwal S, Mathur M, Wasylyk B, Srivastava A. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin. Cancer Res. 2000;6:2440–2447
  46. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003;33:357–365
  47. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, et al.  Higher lung cancer risk for younger African–Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16:2205–2208
  48. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 2000;9:1037–1042
  49. Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res. 2002;62:2819–2823
  50. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 1997;34:577–582
  51. Wang LE, Cheng L, Spitz MR, Wei Q. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003;42:1–8
  52. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63:4327–4330
  53. Pelengaris S, Khan M. The many faces of c-MYC. Arch. Biochem. Biophys. 2003;416:129–136
  54. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375–379
  55. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  56. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1:219–227
  57. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524–6536
  58. Balasubramanian SP, Brown NJ, Reed MW. Role of genetic polymorphisms in tumour angiogenesis. Br. J. Cancer. 2002;87:1057–1065
  59. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, et al. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer. 2001;91:672–678
  60. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, et al.  Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574–3581
  61. Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, et al.  Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood. 2002;100:3037–3040
  62. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62:3369–3372
  63. Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia. 2002;16:1437–1442
  64. Takeuchi S, Takeuchi N, Tsukasaki K, Bartram CR, Zimmermann M, Schrappe M, et al.  Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 2002;119:985–987
  65. Marsh HP, Haldar NA, Bunce M, Marshall SE, le Monier K, Winsey SL, et al.  Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br. J. Cancer. 2003;89:1096–1101
  66. Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, et al.  Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002;100:2263–2265
  67. Shimura T, Hagihara M, Takebe K, Munkhbat B, Odaka T, Kato H, et al.  The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer. 1994;73:1184–1188
  68. Shimura T, Hagihara M, Takebe K, Munkhbat B, Ogoshi K, Mitomi T, et al.  10.5-kb homozygote of tumor necrosis factor-beta gene is associated with a better prognosis in gastric cancer patients. Cancer. 1995;75:1450–1453
  69. Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer. 2000;83:1443–1447
  70. Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, et al.  An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63:3066–3068
  71. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, et al.  Interleukin-6-174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003;63:8051–8056
  72. Zhang W, Lu B, Gil J, Yang D, Groshen S, Lenz H. Interleukin-8 (IL-8) promoter region gene polymorphism predicts pelvic recurrence after chemo-radiation in patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:S382
  73. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001;2:25–31
  74. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, et al. Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res. 2002;12:465–469
  75. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk. Lymphoma. 2003;44:251–255
  76. Nakamura E, Megumi Y, Kobayashi T, Kamoto T, Ishitoya S, Terachi T, et al.  Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin. Cancer Res. 2002;8:2620–2625
  77. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002;3:229–232
  78. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al.  Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002;359:397–401
  79. McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF+61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int. J. Cancer. 2003;107:673–675
  80. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, et al.  Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62:840–847
  81. Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, et al.  Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res. 2003;63:4407–4411
  82. Hefler LA, Ludwig E, Lampe D, Zeillinger R, Leodolter S, Gitsch G, et al.  Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol. Oncol. 2002;86:134–137
  83. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur. J. Cancer Prev. 2002;11:343–350
  84. Medeiros R, Morais A, Vasconcelos A, Costa S, Carrilho S, Oliveira J, et al. Endothelial nitric oxide synthase gene polymorphisms and the shedding of circulating tumour cells in the blood of prostate cancer patients. Cancer Lett. 2003;189:85–90
  85. Medeiros RM, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, et al.  Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin. Cancer Res. 2002;8:3433–3437
  86. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, et al.  Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999;59:4225–4227
  87. Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM, et al. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res. 2001;61:1296–1298
  88. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin. Cancer Res. 2001;7:2344–2346
  89. Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res. 2002;8:3820–3823
  90. Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R. A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett. 2003;200:49–55
  91. Loktionov A, Watson MA, Stebbings WSL, Speakman CTM, Bingham SA. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett. 2003;189:189–196
  92. Ayala F, Corral J, Gonzalez-Conejero R, Sanchez I, Moraleda JM, Vicente V. Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation. Breast Cancer Res. Treat. 2003;80:145–154
  93. Zhang X, Ma X, Zhu QG, Li LC, Chen Z, Ye ZQ. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J. Urol. 2003;170:1379–1382
  94. Kuraoka K, Oue N, Yokozaki H, Kitadai Y, Ito R, Nakayama H, et al. Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. Int. J. Oncol. 2003;23:421–427
  95. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565–573
  96. D. Hanrahan, J. Folkman, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell 86 (1996) 353–364.
  97. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  98. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–248
  99. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001;2:667–673
  100. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812–816
  101. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 2000;37:443–448
  102. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology. 2003;62:374–377
  103. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al.  A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer. 2003;106:468–471
  104. Iughetti P, Suzuki O, Godoi PH, Alves VA, Sertie AL, Zorick T, et al.  A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res. 2001;61:7375–7378
  105. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001;2:149–156
  106. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer. 2002;99:157–166
  107. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205–222
  108. Duffy MJ. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem. Soc. Trans. 2002;30:207–210
  109. Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Integrin beta3 Leu33Pro homozygosity and risk of cancer. J. Natl Cancer Inst. 2003;95:1150–1157
  110. Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, et al.  A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 2000;60:873–876
  111. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Kohshi K, et al.  E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett. 2003;195:53–58
  112. Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA. Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int. J. Cancer. 2002;100:683–685
  113. Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo AM, Magnani M, et al.  Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene. 2002;21:8192–8195
  114. Wu MS, Huang SP, Chang YT, Lin MT, Shun CT, Chang MC, et al.  Association of the -160 C→a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer. 2002;94:1443–1448
  115. Pharoah PD, Oliveira C, Machado JC, Keller G, Vogelsang H, Laux H, et al.  CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int. J. Cancer. 2002;101:196–197
  116. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 1999;8:843–854
  117. Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum. Mol. Genet. 2001;10:2313–2318
  118. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat. Res. 2003;544:9–41
  119. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, Kawachi I, et al.  The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology. 1999;53:121–125
  120. Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, et al.  Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J. Urol. 2000;164:567–572
  121. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res. Treat. 2000;59:153–161
  122. Li AJ, Baldwin RL, Karlan BY. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin. Cancer Res. 2003;9:3667–3673
  123. Edwards SM, Badzioch MD, Minter R, Hamoudi R, Collins N, Ardern-Jones A, et al.  Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer. 1999;84:458–465
  124. Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, et al.  Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer. Anticancer Res. 2002;22:1825–1828
  125. Yang Q, Shan L, Segawa N, Nakamura M, Nakamura Y, Mori I, et al.  Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer. Anticancer Res. 2001;21:197–200
  126. Powell BL, Piersma D, Kevenaar ME, van Staveren IL, Themmen AP, Iacopetta BJ, et al. Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. J. Clin. Endocrinol. Metab. 2003;88:1653–1657
  127. Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, et al.  Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 2000;60:1626–1630
  128. Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, et al.  Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate. 2002;52:269–278
  129. Scorilas A, Bharaj B, Giai M, Diamandis EP. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer. Br. J. Cancer. 2001;84:760–767
  130. van Gils CH, Onland-Moret NC, Roest M, van Noord PA, Peeters PH. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2003;12:1194–1199
  131. Nam RK, Toi A, Vesprini D, Ho M, Chu W, et al.  V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology. 2001;57:199–204
  132. Bharaj B, Scorilas A, Giai M, Diamandis EP. TA repeat polymorphism of the 5alpha-reductase gene and breast cancer. Cancer Epidemiol. Biomarkers Prev. 2000;9:387–393
  133. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997;57:1063–1065
  134. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, et al. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res. 1999;59:2825–2828
  135. Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, et al.  A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer. 2000;87:204–210
  136. Matsui A, Ikeda T, Enomoto K, Nakashima H, Omae K, Watanabe M, et al.  Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase. Cancer Lett. 2000;150:23–31
  137. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res. 1999;59:2332–2334
  138. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr. J. 2001;48:543–549
  139. Ikuyama T, Hamasaki T, Inatomi H, Katoh T, Muratani T, Matsumoto T. Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese. Endocr. J. 2002;49:433–438
  140. Ruggiero M, Pacini S, Aterini S, Fallai C, Ruggiero C, Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol. Res. 1998;10:43–46
  141. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol. Biomarkers Prev. 2003;12:23–27
  142. Wu HC, Lin CC, Chen WC, Chen HY, Tsai FJ. Osteocalcin gene HindIII C/T polymorphism is a biomarker for prostate cancer and responsiveness to hormone therapy. Eur. Urol. 2003;43:197–200
  143. Cai Q, Gao YT, Wen W, Shu XO, Jin F, Smith JR, et al. Association of breast cancer risk with a GT dinucleotide repeat polymorphism upstream of the estrogen receptor-alpha gene. Cancer Res. 2003;63:5727–5730
  144. Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, et al.  Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol. Biomarkers Prev. 2003;12:853–859
  145. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis. 2000;21:623–627
  146. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R. Polymorphisms of estrogen receptor alpha gene in endometrial cancer. Biochem. Biophys. Res. Commun. 2002;297:558–564
  147. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol. Carcinog. 2003;37:202–208
  148. Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, Dahiya R. Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma. Biochem. Biophys. Res. Commun. 2002;296:1200–1206
  149. Zheng SL, Zheng W, Chang BL, Shu XO, Cai Q, Yu H. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res. 2003;63:7624–7629
  150. Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Venter DJ, et al.  The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol. Biomarkers Prev. 2002;11:439–443
  151. De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 2003;63:5236–5238
  152. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl Acad. Sci. USA. 2002;99:12263–12268
  153. Friedberg T. Cytochrome P450 polymorphisms as risk factors for steroid hormone-related cancers. Am. J. Pharmacogenom. 2001;1:83–91
  154. Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr. Rev. 2003;61:227–238
  155. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J. Nutr. 2002;132:2350S–2355S
  156. Loktionov A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). J. Nutr. Biochem. 2003;14:426–451
  157. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu. Rev. Med. 2003;54:437–452
  158. Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta. 2003;1603:99–111
  159. Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur. J. Cancer. 2002;38:639–644
  160. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer. 2003;3:912–920
  161. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J. Pharmacol. 1998;125:879–887
  162. McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, et al.  Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 1999;105:696–700
  163. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 1999;91:2001–2008
  164. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6926
  165. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, et al.  Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 2003;9:3246–3253
  166. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al.  Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 2000;6:4705–4712
  167. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 2001;7:2832–2839
  168. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics. 2002;12:555–558
  169. Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L, et al.  Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol. 2002;13:1915–1918
  170. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, et al.  Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer. 2003;103:294–299
  171. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 2003;9:1611–1615
  172. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004;4:66–72
  173. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 2001;19:1779–1786
  174. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1:65–70
  175. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer. 2001;85:827–830
  176. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 2002;17:46–49
  177. Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, et al.  Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Cancer Res. 2003;9:3700–3704
  178. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al.  New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int. J. Cancer. 2003;104:790–795
  179. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002;100:3832–3834
  180. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood. 2000;95:1222–1228
  181. Howells RE, Holland T, Dhar KK, Redman CW, Hand P, Hoban PR, et al.  Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int. J. Gynecol. Cancer. 2001;11:107–112
  182. Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, et al.  Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001;61:7130–7135
  183. Voso MT, D'Alo F, Putzulu R, Mele L, Scardocci A, Chiusolo P, et al.  Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood. 2002;100:2703–2707
  184. Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS, Radloff GA, et al.  Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002;100:67–71
  185. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2000;10:715–726
  186. Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N, et al.  Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia. 2002;16:203–208
  187. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, et al.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl Acad. Sci. USA. 2001;98:11592–11597
  188. Stoehlmaher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 2002;94:936–942
  189. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int. J. Cancer. 2003;103:810–814
  190. Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 1996;56:3725–3730
  191. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancer Res. 2002;8:802–810
  192. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, et al.  Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J. Natl Cancer Inst. 2002;94:1635–1640
  193. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al.  MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62:4955–4962
  194. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 2003;22:1117–1121
  195. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 2001;21:3075–3079
  196. Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol. Biomarkers Prev. 2003;12:1168–1174
  197. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100:3761–3766
  198. Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP, et al.  An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin. Cancer Res. 2003;9:3012–3020
  199. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001;61:8654–8658
  200. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 2003;3:136–158
  201. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10:217–223
  202. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al.  Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231–234
  203. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 2003;3:330–338

PII: S0304-3835(04)00145-4

doi: 10.1016/j.canlet.2004.02.009

Cancer Letters
Volume 208, Issue 1 , Pages 1-33 , 10 May 2004

Article Tools

* Image Usage & Resolution